Phone: (650) 368 6983 info@airmid.com

Target Portfolio 1. Unmet Needs 2. AIRMID Novel Therapeutic Approach 3. AIRMID's Therapeutic Candidates 4. Excellent Safety Profiles 5. Proof-of-concept data     July 2009 AIRMID partners with Kineta to develop ShK peptides February 2009 Adam Bristol joins AIRMID Board of Directors more...

Home | Autoimmune disease | Multiple sclerosis | Type 1 diabetes mellitus | Kv1.3 Potassium Channel | PAP-1 | ShK Effector memory T cells | Contact | Sitemap Copyrights © 2007, www.airmid.com